All In Biotech

Drug Trial Radar · NCT01633541

Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer

Concomitant Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Bio-selection For Organ Preservation In Patients With Advanced Laryngeal Cancer

Last checked: Nov 19, 2026Latest source record: Jul 20, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

55

Actual

Start

Mar 2012

Primary completion

Nov 6, 2021

Study completion Nov 6, 2021

Sponsor

Lead sponsor
University of Michigan Rogel Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 4, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate a new treatment approach for adults with advanced laryngeal cancer: induction chemotherapy with platinum and docetaxel plus AT-101. AT-101 is an investigational drug for the treatment of advanced cancer. It is hoped that the combination of this chemotherapy regimen will allow cancer patients to keep their voice box and to improve/maintain voice-related quality of life. The ultimate goal of this study is to prevent the surgery to remove subjects voice box.

Conditions

  • Laryngeal Cancer

Interventions

  • AT-101Drug

    Patients will receive AT-101 40 mg orally two times a day.

  • DocetaxelDrug

    Docetaxel (Taxotere) 75 mg/m2

  • CisplatinDrug

    Cisplatin 100 mg/m2

  • CarboplatinDrug

    Carboplatin AUC (area under the curve) 6. Maximum dose of 700 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Patients Alive and Free From Indication for Laryngectomy Three Months Post TreatmentTime frame: Up to 3 months after end of treatment
  2. Progression-free SurvivalTime frame: Up to 3 years after randomization
  3. Overall Response Rate (ORR)Time frame: Up to approximately 60 days
  4. Percentage of Patients Experiencing Grade 3 or Higher Adverse Events.Time frame: Up to 3 years after end of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Michigan Comprehensive Cancer Center

    Ann Arbor, Michigan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.